FXN and Friedreich ataxia: In different FRDA mouse models, gene therapy using injection of adeno‐associated virus expressing FXN either intrathecally or in peripheral blood led to increased FXN levels throughout the CNS as well as neurological symptoms improvement.55, 56 In future studies addressing the effects of such FXN‐restoring therapies in FRDA patients, neuromagnetic rsFC could potentially contribute to select the optimal time‐point to start the treatment and monitor their effects on FRDA patients' intrinsic functional brain architecture.